Citation of this article
Corresponding Author of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (2797)
All Articles published online
|
Jun 21, 2007 (publication date) through Nov 26, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Yoshiji H, Noguchi R, Yamazaki M, Ikenaka Y, Sawai M, Ishikawa M, Kawaratani H, Mashitani T, Kitade M, Kaji K, Uemura M, Yamao J, Fujimoto M, Mitoro A, Toyohara M, Yoshida M, Fukui H. Combined treatment of vitamin K2 and angiotensin-converting enzyme inhibitor ameliorates hepatic dysplastic nodule in a patient with liver cirrhosis. World J Gastroenterol 2007; 13(23): 3259-3261 [PMID: 17589909 DOI: 10.3748/wjg.v13.i23.3259] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v13/i23/3259.htm |
| Number | Citing Articles |
| 1 |
Tian-hao Liu, Ming-hao Chen, Wan-qing Tu, Qiu-er Liang, Wen-cong Tao, Zhen Jin, Ya Xiao, Li-guo Chen. Network and 16S rRNA Sequencing-Combined Approach Provides Insightal Evidence of Vitamin K2 for Salt-Sensitive Hypertension. Frontiers in Nutrition 2021; 8 doi: 10.3389/fnut.2021.639467
|
| 2 |
Parneet Kaur, Arunachalam Muthuraman, Manjinder Kaur. The Implications of Angiotensin-Converting Enzymes and Their Modulators in Neurodegenerative Disorders: Current and Future Perspectives. ACS Chemical Neuroscience 2015; 6(4): 508 doi: 10.1021/cn500363g
|
| 3 |
|
| 4 |
HITOSHI YOSHIJI, RYUICHI NOGUCHI, YASUHIDE IKENAKA, KOSUKE KAJI, YUSAKU SHIRAI, YOSUKE AIHARA, JUNICHI YAMAO, MASAHISA TOYOHARA, AKIRA MITORO, MASAYOSHI SAWAI, MOTOYUKI YOSHIDA, CHIE MORIOKA, MASAO FUJIMOTO, MASAHITO UEMURA, HIDETO KAWARATANI, TATSUHIRO TSUJIMOTO, HIROSHI FUKUI. Soluble VEGF receptor-2 may be a predictive marker of anti-angiogenic therapy with clinically available safe agents. Oncology Letters 2011; 2(1): 69 doi: 10.3892/ol.2010.196
|
| 5 |
Quanxiang Yan, Tao Zhang, Christine O'Connor, James W. Barlow, John Walsh, Gaia Scalabrino, Feng Xu, Helen Sheridan. The biological responses of vitamin K2: A comprehensive review. Food Science & Nutrition 2023; 11(4): 1634 doi: 10.1002/fsn3.3213
|
| 6 |
Sameh Saber. Angiotensin II: a key mediator in the development of liver fibrosis and cancer. Bulletin of the National Research Centre 2018; 42(1) doi: 10.1186/s42269-018-0020-7
|
| 7 |
Halima Sultana, Michio Komai, Hitoshi Shirakawa. The Role of Vitamin K in Cholestatic Liver Disease. Nutrients 2021; 13(8): 2515 doi: 10.3390/nu13082515
|
| 8 |
Marina C. Vera, Florencia Lorenzetti, Alvaro Lucci, Carla G. Comanzo, María P. Ceballos, Gerardo B. Pisani, María de L. Alvarez, Ariel D. Quiroga, María C. Carrillo. Vitamin K2 supplementation blocks the beneficial effects of IFN-α-2b administered on the early stages of liver cancer development in rats. Nutrition 2019; 59: 170 doi: 10.1016/j.nut.2018.08.016
|
| 9 |
Hitoshi Yoshiji, Ryuichi Noguchi, Masahisa Toyohara, Yasuhide Ikenaka, Mitsuteru Kitade, Kosuke Kaji, Masaharu Yamazaki, Junichi Yamao, Akira Mitoro, Masayoshi Sawai, Motoyuki Yoshida, Masao Fujimoto, Tatsuhiro Tsujimoto, Hideto Kawaratani, Masahito Uemura, Hiroshi Fukui. Combination of vitamin K2 and angiotensin-converting enzyme inhibitor ameliorates cumulative recurrence of hepatocellular carcinoma. Journal of Hepatology 2009; 51(2): 315 doi: 10.1016/j.jhep.2009.04.011
|
| 10 |
T Rosenthal, I Gavras. Angiotensin inhibition and malignancies: a review. Journal of Human Hypertension 2009; 23(10): 623 doi: 10.1038/jhh.2009.21
|
| 11 |
Michele Barone, Maria Teresa Viggiani, Giuseppe Losurdo, Mariabeatrice Principi, Alfredo Di Leo. Systematic review: Renin-angiotensin system inhibitors in chemoprevention of hepatocellular carcinoma. World Journal of Gastroenterology 2019; 25(20): 2524-2538 doi: 10.3748/wjg.v25.i20.2524
|